Literature DB >> 1309480

Adrenergic receptor function in fat cells.

P Arner1.   

Abstract

All classical adrenoceptor subtypes are functionally expressed in fat cells. However, only beta 1 adrenoceptors appear to be present in all types of fat cells. There is a substantial adrenoceptor reserve in fat cells; approximately 50% of beta and alpha 2 adrenoceptors are spare receptors. Beta adrenoceptors are subject to intensive regulation. They are regulated by insulin, estrogens, and androgens as well as by thyroid hormones and are altered by nutritional factors, diabetes, autonomic neuropathy, and beta-blocking treatment. Alpha receptors are less sensitive to changes except during infancy, when there are marked developmental alterations in the function of alpha 2 adrenoceptors, and during fasting, when there is a decrease in receptor expression. In addition, beta adrenoceptors but not alpha 2 adrenoceptors are sensitive to homologous desensitization after exposure to agonists. Site variations in the expression and function of beta and alpha 2 adrenoceptors, which in part are situated at the level of gene transcription, may be involved in the development of regional obesity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309480     DOI: 10.1093/ajcn/55.1.228s

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  16 in total

Review 1.  Counterregulation of insulin by leptin as key component of autonomic regulation of body weight.

Authors:  Katarina T Borer
Journal:  World J Diabetes       Date:  2014-10-15

2.  Dynamic strength training improves insulin sensitivity and functional balance between adrenergic alpha 2A and beta pathways in subcutaneous adipose tissue of obese subjects.

Authors:  J Polak; C Moro; E Klimcakova; J Hejnova; M Majercik; N Viguerie; D Langin; M Lafontan; V Stich; M Berlan
Journal:  Diabetologia       Date:  2005-11-05       Impact factor: 10.122

3.  Intraneural stimulation elicits an increase in subcutaneous interstitial glycerol levels in humans.

Authors:  C Dodt; P Lonnroth; H L Fehm; M Elam
Journal:  J Physiol       Date:  1999-12-01       Impact factor: 5.182

4.  Functional evidence that alpha 2A-adrenoceptors are responsible for antilipolysis in human abdominal fat cells.

Authors:  G Tarkovács; C Blandizzi; E S Vizi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

5.  Effect of oleoyl-estrone treatment on the expression of beta1- beta2- and beta3-adrenoreceptors in rat adipose tissues.

Authors:  C Cabot; M del Mar Grasa; J A Fernández-López; M Alemany
Journal:  Mol Cell Biochem       Date:  2001-05       Impact factor: 3.396

6.  White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis.

Authors:  Lei Cao; Eugene Y Choi; Xianglan Liu; Adam Martin; Chuansong Wang; Xiaohua Xu; Matthew J During
Journal:  Cell Metab       Date:  2011-09-07       Impact factor: 27.287

7.  Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.

Authors:  S Reynisdottir; K Ellerfeldt; H Wahrenberg; H Lithell; P Arner
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue.

Authors:  P Barbe; L Millet; J Galitzky; M Lafontan; M Berlan
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  Changes of testicular phosphorylated proteins in response to restraint stress in male rats.

Authors:  Supatcharee Arun; Jaturon Burawat; Wannisa Sukhorum; Apichakan Sampannang; Nongnut Uabundit; Sitthichai Iamsaard
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

10.  Cholinoceptor-mediated effects on glycerol output from human adipose tissue using in situ microdialysis.

Authors:  K Andersson; P Arner
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.